Your passion for science and your commitment to excellence are humbling. I wish Evotec long-term success." Dr Christian Wojczewski, Chief Executive Officer of Evotec, added: "On behalf of the ...

strengthen the long-term profitability of the company, and deliver significant value to shareholders." The offer came after a difficult period for Evotec, with falling revenues resulting from a ...

I am a master's graduate from USTC, currently working at ModelScope. I have a passion for deep learning and welcome to communicate.

Novo Nordisk and Evotec select three projects from Boston University ... will characterize potential modulators of metabolic disease by investigating molecular mechanisms related to bariatric surgery.

At close: December 20 at 4:00:03 PM EST ...

Commissions do not affect our editors' opinions or evaluations. Long-term care insurance isn’t as prevalent as other types of insurance, despite the fact that long-term care may eventually ...

The JV has been formed German pharma companies Boehringer Ingelheim and Evotec with in vitro diagnostics specialist bioMérieux, with the objective of developing new antimicrobial drugs backed by ...

Evotec (EVO) announced that its Chief Operating Officer, Dr Craig Johnstone, will step down and leave the company effective December 31. Dr Johnstone joined Evotec in May 2012 as SVP Drug ...

LAB eN 2, the drug discovery accelerator launched by Evotec and Novo Nordisk in September 2023, has unveiled its first three projects and launched an expansion featuring five new academic partners.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

(RTTNews) - Novo Nordisk and Evotec have selected three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center for development ...